Verastem Falls on Halted Phase 2 Enrollment
Verastem has announced that it has stopped enrollment in its Phase 2 study of VS-6063 for patients with mesothelioma.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 245How the Top Biotechs Handled the Valuation Shock
24/7 Wall St. has taken a look at some of the largest biotech companies and highlighted the damage that a single tweet did to them last week.
3 Top Jefferies Biotech Picks to Buy on Recent Sector Weakness
In a recent research report, Jefferies highlighted three top biotech companies that are very tempting buys now.
Short Sellers Boost Positions in Major Pharma
The September 15 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest has increased.
Short Sellers Increase Bets in Major Biotech
The September 15 short interest data have been compared with the previous figures, and short interest in these selected stocks increased across the board for this settlement date.
Why Oppenheimer Says Alexion Is a Cheap Buy Now
Oppenheimer maintained its Outperform rating for Alexion Pharmaceuticals with a price target that implies upside of more than 40%.
Merrill Lynch Has 4 Pharma Stocks to Buy Against Political Chatter
One positive from the hammering the pharmaceutical stocks have taken is the Merrill Lynch analysts say investors have been given a golden opportunity to buy the top companies at much better prices.
Arrowhead Jumps in Anticipation of Analyst Day
Arrowhead Research shares soared in early trading indications Thursday in anticipation of its analyst day.
Conatus Pharmaceuticals Soars on Positive Phase 2 Results
Conatus Pharmaceuticals has announced that its exploratory Phase 2 portal hypertension clinical trial of emricasan met its primary endpoints.
Why Key Analyst Sees 25% Upside in Intuitive Surgical
Canaccord Genuity reiterated a Buy rating on Intuitive Surgical with a price target that implies upside of 25% from current prices.
Intra-Cellular Sets Price for Secondary Offering
Intra-Cellular Therapies is gearing up for its secondary offering, and in preparation it just set the price.
Heron Therapeutics Soars on Positive Phase 2 Results
Heron Therapeutics Inc. (NASDAQ: HRTX) is bucking the trend of a biotechs and pharmas selling off in the wake of Hillary’s tweet. In fact the company was one of those leading the health care…
What Signal Genetics Gets With New Master Service Agreement
ThinkstockSignal Genetics Inc. (NASDAQ: SGNL) soared right out of the gate Wednesday morning on word of a new agreement. Basically, the company announced the signing of a master service agreement (MSA) with a leading…
Orexigen Therapeutics Receives $15 Million Milestone Payment
Orexigen Therapeutics has announced receipt of the first of three potential $15 million anniversary milestone payments from Takeda Pharmaceuticals.
How Key Analyst Sees PBMs Responding to Hillary’s Tweet
The recent outcry on social media, focusing on drug pricing, is likely to draw attention to the role of pharmacy benefit managers.